Business Context and Reporting Period
This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2017. The filing identifies the registrant as PowerVerde, Inc., formerly known as Vyrex Corporation; the request metadata identifies 374Water Inc. The company is developing clean-energy electric power generation systems, but its planned principal operations had not commenced. Reported revenue continued to come from legacy Biotech IP licensing and a new manufacturing assembly agreement.
Financial Results and Position
| Metric | Three Months Ended September 30, 2017 | Nine Months Ended September 30, 2017 |
|---|---|---|
| Revenue | $133,686 | $473,485 |
| Operating income | $9,680 | $140,192 |
| Net income | $4,090 | $116,516 |
| Operating margin | Approximately 7.2% | Approximately 29.6% |
| Net margin | Approximately 3.1% | Approximately 24.6% |
| Operating cash flow | Not separately reported | $227,690 |
- Third-quarter revenue consisted of $108,686 of Biotech IP licensing fees and $25,000 of Liberty assembly revenue. No revenue came from sales of the company’s planned clean-energy systems.
- Nine-month revenue included $448,484 of Biotech IP licensing fees and $25,000 of Liberty assembly revenue.
- Cash and cash equivalents were $7,476 at September 30, 2017, compared with $4,786 at December 31, 2016.
- Working capital was negative $128,270 at September 30, 2017, improved from negative $272,120 at year-end 2016.
- Current liabilities were $280,766, including $200,000 owed to related parties. Total assets were $256,382, resulting in stockholders’ deficiency of $24,384.
- The company generated $227,690 of operating cash flow and used $225,000 for principal payments on related-party notes during the first nine months.
- Research and development expense was $172,760 for the nine months, down from $282,339 in the prior-year period. General and administrative expense was $160,533, down from $262,599.
Material Changes Versus the Prior Comparable Period
- Third-quarter revenue increased to $133,686 from $89,118, while nine-month revenue increased to $473,485 from $417,074.
- The company reported third-quarter net income of $4,090 versus a net loss of $161,590 in the prior-year quarter, and nine-month net income of $116,516 versus a net loss of $173,761.
- Operating expenses declined substantially, primarily because of lower stock-based compensation, employee salaries, and other compensation-related costs.
- Interest expense declined to $5,589 in the third quarter and $23,726 for the nine months, compared with $17,338 and $45,898, respectively, in the prior-year periods.
- The company entered into the Liberty manufacturing agreement in April 2017, built and shipped 25 Hydra systems by September 30, and recorded $25,000 of related revenue.
- Liberty accounts receivable of $25,000 were converted into a 12% promissory note maturing January 31, 2018.
- The company wrote off $38,750 paid toward Helidyne expanders because of Helidyne’s failure to perform under the agreement.
Guidance, Outlook, Risks, and Unusual Items
- Management expected 2017 Biotech IP revenue to approximate 2016 levels, but stated that this was not assured.
- The Biotech IP licensing agreement, which has generated all company revenue since 2012 before the Liberty assembly revenue, expires in March 2018. The company expects no further royalty revenue from that agreement after expiration.
- The company stated that it needs to raise substantial additional capital and that failure to do so could force it to cease operations.
- As of October 2017, $150,000 remained outstanding under secured related-party notes due April 30, 2018, bearing 10% interest and collateralized by Biotech IP receivables. Management intended to apply most 2017 and 2018 Biotech IP revenue toward these obligations.
- Management planned to reduce salary and consulting expenses and pursue additional manufacturing services through the Liberty relationship.
- The filing states that substantial losses are expected to continue until the company successfully commercializes and markets its clean-energy systems, with no assurance that commercialization will occur.
- The company reported no material changes to previously disclosed risk factors, no legal proceedings, and effective disclosure and internal control procedures as of September 30, 2017.
Important Facts to Verify
- Confirm the registrant’s current corporate name and whether this filing corresponds to 374Water Inc., as the filing itself identifies PowerVerde, Inc.
- Verify the timing and collectibility of the $25,000 Liberty promissory note due January 31, 2018.
- Assess the company’s ability to replace licensing revenue after the March 2018 expiration and to commercialize its clean-energy systems.
- Review the maturity, collateral, extensions, and repayment capacity for the related-party notes due April 30, 2018.
- Evaluate liquidity risk, including the $128,270 working capital deficit and the company’s stated dependence on additional financing.
- Monitor the Helidyne agreement, including the $38,750 write-off and potential future royalty commitments if the company produces expanders using Helidyne technology.